Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

Inclusion Criteria: * Patients who are more than 20 and less than 80 years old. * Patients whose expected life expectancy is at least 16 weeks (4 months). * Patients who receive liver transplants exceeding the Milan Criteria. * ECOG Performance Status (ECOG-PS) score is 0-2. * Patients who satisfy the following conditions of the blood test and kidney, liver function test. Absolute neutrophil count \> 500x10\^6L Hemoglobin ≥ 7.5 g/dL Platelet count \> 20,000/㎣ Total bilirubin \< 15mg/㎗ •Patients who have agreed to participate in the study voluntarily by signing on informed consent form. Exclusion Criteria: * Patients who have received in vitro radiation therapy, systemic chemotherapy within 4 weeks based on sign date of Informed consent form. * Patients who undergo ABO incompatible Liver Transplantation. * Patients who had previously administered cell therapy. * Patients who are confirmed with Acquired Immune Deficiency Syndrome (AIDS). * Patients who are currently receiving dialysis. * Patients who participated in another clinical trial and received treatment in 4 weeks or have a plan for administration of another clinical trial treatment since Informed consent form sign date. * Patients who have uncontrollable or serious disease. * Patients who are unable to use appropriate methods of contraception during the study period. * Patient whose tumor has not been removed or liver metastasis is confirmed.